Common Stock, $0.001 par value
- Symbol
- CATX
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Perspective Therapeutics, Inc.
CATXNYSE_AMERICANEQUITYCurrent
Other Events
Item 8.01 Other Events. On October 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Company context
Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, creating an opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.
Current securities
Registered securities in this filing
Perspective Therapeutics, Inc. · 8-K · Filed 2026-10-01
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On October 1, 2026, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Filed exhibits (1)
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology Designed to be the Most Potent Payload in Targeted Oncology Three Independent Clinical-Stage Programs, Each Against a Distinct Target with Data in 2026 Deep Leadership Across Radiopharmaceutical and Drug Development The Perspective Story in Four Parts Radiopharmaceutical Therapy: A Category Still Early in Its Adoption Curve Targeted Delivery of Payloads is Transforming Oncology Therapy $45 Billion+ Addressable Market, Already Generating Blockbuster Radiopharmaceutical Revenue VMT-α-NET, VMT01, PSV359, and PSV594 Address a Combined $45B+ Solid Tumor Market Pipeline in Depth: The Data Behind Each Program Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals Neuroendocrine Tumors VMT-α-NET SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2 Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-α-NET Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis VMT-α-NET Best Response Deepens Over Time VMT-α-NET Responses Deepen Over Time Spider Plot…
Open exhibit ↗